/TLIS
TLIS Stock - Talis Biomedical Corporation
Healthcare|Medical - DevicesOTC
$2.84+77.50%
+$1.24 (+77.50%) • Dec 18
71
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.92
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.67
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $3.12
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for TLIS
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$2.81 – $2.87
TARGET (TP)$3.27
STOP LOSS$2.61
RISK/REWARD1:1.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta1.32
52W High$2.84
52W Low$1.04
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|
| Revenue | $412,000 | $3.65M | N/A | $10.94M | $3.98M |
| Gross Profit | $371,000 | $-4,739,000 | $-2,621,000 | $9.56M | $3.98M |
| Gross Margin | 90.0% | -129.8% | N/A | 87.4% | 100.0% |
| Operating Income | $-66,815,000 | $-112,706,000 | $-200,009,000 | $-91,184,000 | $-26,699,000 |
| Net Income | $-62,007,000 | $-113,012,000 | $-190,458,000 | $-91,076,000 | $-27,432,000 |
| Net Margin | -15050.2% | -3094.5% | N/A | -832.7% | -689.8% |
| EPS | $-34.12 | $-63.65 | $-126.13 | $-314.06 | $-182.88 |
Company Overview
Talis Biomedical Corporation operates as a molecular diagnostic company. The company is developing the Talis One system to address limitations of existing point-of-care diagnostic testing technologies for infectious diseases. It also offers Talis One COVID-19 Test System, which focuses on detection of SARS-CoV-2, the virus that causes COVID-19. In addition, it develops Talis One assay kit for respiratory infections, infections related to women's health, and sexually transmitted infections; and other tests for the detection of other respiratory infections, such as a respiratory panel test to detect influenza A, influenza B, and respiratory syncytial virus. Talis Biomedical Corporation was incorporated in 2013 and is headquartered in Menlo Park, California.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
TLISBeat Rate
21%
Last 14 quarters
Avg Surprise
-218.9%
EPS vs Estimate
Beats / Misses
3/11
Last 12 quarters
Latest EPS
$-4.86
Q3 2024
EPS Surprise History
Q4 22
-32.5%
$-14.69vs$-11.09
Q1 23
-31.6%
$-14.99vs$-11.39
Q2 23
-1256.2%
$-9.90vs$-0.73
Q3 23
-1032.9%
$-8.27vs$-0.73
Q4 23
-16.9%
$-8.62vs$-7.37
Q1 24
-10.7%
$-7.39vs$-6.68
Q2 24
-8.6%
$-7.15vs$-6.58
Q3 24
+17.8%
$-4.86vs$-5.91
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Aug 18, 2025 | — | — | — | — |
Q2 2025 | May 6, 2025 | — | — | — | — |
Q1 2025 | Jan 17, 2025 | — | — | — | — |
Q4 2024 | Dec 27, 2024 | — | — | — | — |
Q3 2024 | Aug 19, 2024 | $-5.91 | $-4.86 | +17.8% | ✓ BEAT |
Q2 2024 | May 8, 2024 | $-6.58 | $-7.15 | -8.6% | ✗ MISS |
Q1 2024 | Mar 28, 2024 | $-6.68 | $-7.39 | -10.7% | ✗ MISS |
Q4 2023 | Nov 14, 2023 | $-7.37 | $-8.62 | -16.9% | ✗ MISS |
Q3 2023 | Aug 10, 2023 | $-0.73 | $-8.27 | -1032.9% | ✗ MISS |
Q2 2023 | May 11, 2023 | $-0.73 | $-9.90 | -1256.2% | ✗ MISS |
Q1 2023 | Mar 22, 2023 | $-11.39 | $-14.99 | -31.6% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-11.09 | $-14.69 | -32.5% | ✗ MISS |
Q3 2022 | Aug 2, 2022 | $-12.29 | $-15.14 | -23.2% | ✗ MISS |
Q2 2022 | May 10, 2022 | $-17.09 | $-18.74 | -9.7% | ✗ MISS |
Q1 2022 | Mar 15, 2022 | $-1.28 | $-1.26 | +1.6% | ✓ BEAT |
Q4 2021 | Nov 15, 2021 | $-25.04 | $-22.34 | +10.8% | ✓ BEAT |
Q3 2021 | Aug 10, 2021 | $-13.04 | $-37.63 | -188.6% | ✗ MISS |
Q2 2021 | May 11, 2021 | $-11.84 | $-69.12 | -483.8% | ✗ MISS |
Q1 2021 | Mar 30, 2021 | — | $-33.69 | — | — |
Q1 2021 | Jan 22, 2021 | — | $-101.53 | — | — |
Latest News
Loading news...
Frequently Asked Questions about TLIS
What is TLIS's current stock price?
Talis Biomedical Corporation (TLIS) is currently trading at $2.84 per share. The stock has moved +77.50% today.
What is the analyst price target for TLIS?
No analyst price targets are currently available for this stock.
What sector is Talis Biomedical Corporation in?
Talis Biomedical Corporation operates in the Healthcare sector, specifically within the Medical - Devices industry. The company is traded on the OTC exchange.
What is TLIS's market cap?
Talis Biomedical Corporation has a market capitalization of $0.01 billion, making it a small-cap company.
Does TLIS pay dividends?
No, Talis Biomedical Corporation does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBNVIF
Binovi Technologies Corp.
$0.00
Mkt Cap: $0.0B
HAVLF
HAVN Life Sciences Inc.
$0.00
Mkt Cap: $0.0B
IRME
IR-Med Inc.
$0.04
Mkt Cap: $0.0B
LLBO
Lifeline Biotechnologies, Inc.
$0.00
Mkt Cap: $0.0B
NRPR
Resilient Healthcare Corp
$0.05
Mkt Cap: $0.0B
NUMD
Nu-Med Plus, Inc.
$0.02
Mkt Cap: $0.0B
PLLWF
Polarean Imaging plc
$0.00
Mkt Cap: $0.0B
RQHTF
Reliq Health Technologies Inc.
$0.01
Mkt Cap: $0.0B
SYDRF
Delota Corp.
$0.10
Mkt Cap: $0.0B
TBRIF
Therma Bright Inc.
$0.04
Mkt Cap: $0.0B
Explore stocks similar to TLIS for comparison